← SynDRA
FUTIBATINIB
SynDRA canonical compound SYN0038410 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | FGF2 | FGFR1 |
|---|
| Mechanism of action | FGFR inhibitor |
|---|
All known targets
- FGFR1
- FGFR2
- FGFR3
- FGFR4
- BTK
- FGF2
Mechanisms of action (all sources)
- FGFR3 INHIBITOR
- Fibroblast growth factor receptor inhibitor
- FGFR1 INHIBITOR
- FGFR4 INHIBITOR
- FGFR2 INHIBITOR
- FGFR inhibitor
Drug classes
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- lytgobi
- TAS-120
- Fgfr-in-1
- Lytgobi
- 4B93MGE4AL
- TAS 120
- futibatinibum
- RefChem:57740
- Futibatinib [USAN]
- TAS120
- UNII-4B93MGE4AL
- TAS 120 [WHO-DD]
- WHO 10879
- TAS-120 (Futibatinib)
- C22H22N6O3
- Lytgobi (TN)
- MFCD29037352
- Futibatinib (Standard)
- FUTIBATINIB [INN]
- FUTIBATINIB [JAN]
- FUTIBATINIB [WHO-DD]
- Futibatinib (JAN/USAN/INN)
- GTPL9786
- orb1302144
- SCHEMBL15345470
- BDBM161389
- GLXC-21244
- EX-A1862
- NSC813488
- AKOS032945115
- CS-6031
- Example 2 [WO2013108809]
- HY-100818R
- NSC-813488
- NCGC00522487-01
- AC-35460
- BS-15425
- DA-53179
Look up FUTIBATINIB in the interactive SynDRA portal →